Protalix BioTherapeutics, Inc. (PLX): Submission of Matters to a Vote of Security Holders
Protalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 plx-20260625xex10d1.htm EX-10.1 Exhibit 10.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN ( Amended and Restated as of June 25, 2026 ) 1. Purposes of the Plan . The purposes of this Plan are to attract and retain the best available per
How this was made
The 30-second read
Why it matters
This is primarily a governance/compensation disclosure. Without vote outcomes or quantified changes to the equity pool in the provided text, the immediate tradable catalyst is limited to monitoring the upcoming/ongoing shareholder vote and any resulting plan terms.
Market read
Traders may treat this as a low-impact catalyst unless the full filing reveals material changes to the equity incentive plan that affect dilution/overhang.
What to watch
Traders should check the full 8-K for the specific proposal(s), voting results/timing, and any plan limits (share pool size, burn rate, option/SAR mix) that could change dilution expectations.
Background
The SEC 8-K (Item 5.07) indicates PLX submitted matters to a vote of security holders and attached an amended and restated stock incentive plan (Exhibit 10.1) effective June 25, 2026.
Ticker impact
PLX filed an 8-K for Item 5.07, submitting matters to a vote of security holders alongside an amended and restated stock incentive plan.
Near-term price impact is likely limited unless the vote results or plan terms materially change share issuance/dilution expectations.
The excerpt shows an amended and restated 2006 stock incentive plan attached as Exhibit 10.1, but provides no vote outcomes, share-count changes, or quantified dilution/financial targets.
Market effects
Minimal; equity-plan amendments are company-specific and typically do not reset sector fundamentals.
None indicated.
None indicated.
Counterpoint
Even without quantified terms in the excerpt, equity-plan amendments can sometimes signal a shift toward more SBC-heavy compensation, which could weigh on valuation if dilution is higher than investors expect.
Key entities
- companyProtalix BioTherapeutics, Inc.
Subject of the SEC 8-K filing; submitted matters to a vote and attached an amended and restated stock incentive plan.
- regulatory_filingSEC Form 8-K
The filing type used to disclose the submission of matters to a vote of security holders and related exhibits.
